Sung Lee sold $3.2M of CYTK
EVP, Chief Financial Officer at CYTOKINETICS INC. 38,730 shares at an average of $82.30, traded Jun 24, 2026, filed Jun 29, 2026.
Score components
- +22RoleCFO
- +25Trade size$3.2M at market
- +10Share of holdings soldSold 38% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001061983-26-000071, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 24, 2026 | MOption exercise Common Stock10b5-1 | +23,370 | $48.51 | $1.1M | 86,591 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Common Stock10b5-1 | +9,307 | $44.36 | $413k | 95,898 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Common Stock10b5-1 | +2,817 | $44.36 | $125k | 98,715 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Common Stock10b5-1 | +1,113 | $48.51 | $54k | 99,828 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Common Stock10b5-1 | +188 | $44.36 | $8,340 | 100,016 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Common Stock10b5-1 | +822 | $44.36 | $36k | 100,838 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Common Stock10b5-1 | +1,113 | $48.51 | $54k | 101,951 | Jun 29, 2026 |
| Jun 24, 2026 | SOpen-market sale Common Stock10b5-1 | -38,730 | $82.30 | $3.2M | 63,221 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -23,370 | $0.00 | $0 | 30,047 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -9,307 | $0.00 | $0 | 32,019 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Incentive Stock Option (Right to Buy)derivative10b5-1 | -2,817 | $0.00 | $0 | 6,199 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -1,113 | $0.00 | $0 | 28,934 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Incentive Stock Option (Right to Buy)derivative10b5-1 | -188 | $0.00 | $0 | 6,011 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -822 | $0.00 | $0 | 31,197 | Jun 29, 2026 |
| Jun 24, 2026 | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -1,113 | $0.00 | $0 | 27,821 | Jun 29, 2026 |
Related signals
Other insiders at CYTOKINETICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 20, 2026 | CYTOKINETICS INC | Robert I Blum President & CEO | $472k 7,500 shares | -3% | |
| 0Weak | CYTOKINETICS INC | Fady Ibraham Malik EVP Research & Development | $215k 3,500 shares | -2% | |
| 23Weak | CYTOKINETICS INC | Robert I Blum President & CEO | $491k 7,500 shares | -3% | |
| 8Weak | CYTOKINETICS INC | Fady Ibraham Malik EVP Research & Development | $239k 3,500 shares | -2% | |
| 40Moderate | CYTOKINETICS INC | Robert I Blum President & CEO | $7.3M 105,426 shares | -27% | |
| 23Weak | CYTOKINETICS INC | Robert E Landry director | $72k 1,000 shares | -11% | |
| 18Weak | CYTOKINETICS INC | Robert E Landry director | $75k 1,000 shares | -10% | |
| 8Weak | CYTOKINETICS INC | Fady Ibraham Malik EVP Research & Development | $264k 3,500 shares | -2% | |
| 35Weak | CYTOKINETICS INC | B Lynne Parshall director | $357k 5,000 shares | -32% | |
| 23Weak | CYTOKINETICS INC | Robert I Blum President & CEO | $527k 7,500 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.